Cancer Immunotherapy Conference London 2027

Why London for IO sponsors

A cancer immunotherapy conference in London built around programme teams

ImmunoMark Summit is a two-day cancer immunotherapy conference in London on 3–4 March 2027, and its Stream 1, Next-Gen Immuno-Oncology, is given over to the programmes your business sells into: CAR-T and TCR-T, multispecific engagers, myeloid checkpoints, combination regimens and tumour microenvironment modulation.

If you sell research tools, immune-monitoring and cytometry services, cell therapy manufacturing or IO trial delivery, the people in this room are buyers rather than peers. They run discovery, translational, CMC and clinical work inside biotech and pharma, and most of them are at the point of choosing who they work with next. Unlike a purely academic tumour immunology conference in London, the programme is weighted towards industry: 55–60% of delegates come from biotech and pharma, and 45–50% hold senior leadership roles.

The 2nd annual edition targets 400+ delegates. The first London edition, in March 2026, gives you the baseline to judge it on:

300+attendees at London 2026

100+companies represented

70%senior decision-makers

15–25meetings per sponsor

Companies that took part in 2026 included GSK, Roche, AstraZeneca, Bristol Myers Squibb, Incyte and Pierre Fabre, alongside UK cell and immunotherapy biotechs such as Leucid Bio, Laverock Therapeutics, LabGenius Therapeutics, Theolytics and Oxford Vacmedix. That mix of large pharma and venture-backed IO companies is what makes this immunotherapy conference in London worth a line in your 2027 plan.

London Stream 1 agenda

Which Stream 1 sessions open which sales conversations

Every session below is on the London 2027 Stream 1 agenda. The right-hand column is our view of the vendor conversation each one tends to start, so you can line up 1:1 targets and booth messaging before you arrive.

When	Session (speaker as listed)	Conversation it opens for sponsors
Day 1, 09:30	Keynote: Myeloid-Targeted Immunotherapies: Clinical Lessons from MDS and Solid Tumor Studies (Petri Bono, Faron Pharmaceuticals)	Immune-monitoring labs and myeloid-panel assay providers
Day 1, 11:45	AI protein design work and our various other digital initiatives (Marc Siggel, Merck KGaA, Darmstadt, Germany)	Computational design, protein engineering and data platforms
Day 1, 12:15	CARKey: A multi-antigen specific logic-gated CAR T platform designed to overcome antigen heterogeneity in solid tumours (John Bridgeman, ImmunoKey Ltd)	Cell therapy CDMOs, vector and gene-editing suppliers, CAR characterisation tools
Day 1, 14:45	Panel: Scaling Immunotherapies from Discovery to Commercialisation	CDMOs, CMC consultancies, process analytics
Day 1, 17:15	Precision Safety Management & Risk Mitigation in IO	Safety services, cytokine and immune-toxicity monitoring
Day 1, 17:45	Clinical Trial Design in Immunotherapy: Adaptive & Biomarker-Driven Models	CROs running IO trials, central and specialty labs
Day 2, 09:00	Keynote: Next-Gen Combo Immunotherapies (Ivan Diaz-Padilla, Ipsen)	Combination-trial CROs and translational biomarker labs
Day 2, 09:30	Therapeutic Targeting of Human LILRBs: A Novel Class of Myeloid Checkpoint Inhibitors (Ali Roghanian, University of Southampton)	Antibody, reagent and flow cytometry suppliers
Day 2, 11:45	Allogeneic Cellular Therapies (Salah Mansour, University of Southampton)	Cell sourcing, manufacturing and release-testing providers
Day 2, 15:00	Investment & Partnership Models in Immunotherapy (panellist: Simon Brunner, Flagship Pioneering)	Partnering-led vendors and platform companies
Day 2, 16:00	Bispecific and Multispecific Immune Engagers	Developability, bioassay and potency-testing CROs

Stream 1 also carries Leucid Bio, Autolus and Novartis cell therapy and CMC expertise on its speaker panel, which is useful context if your offer is manufacturing or analytical. If your product sits closer to assays and diagnostics, compare this with the Stream 2 view on our biomarker conference London page.

Who you meet

What an immuno-oncology conference in the UK should deliver for your team

Four vendor types get the most from Stream 1 in London. Here is who each should be booking, and where to be in the room.

IO research-tool vendors

Target discovery heads and principal scientists
Day 1 AI protein design and CARKey sessions
Booth demos in the breaks after those talks

Immune-monitoring and cytometry labs

Translational medicine and biomarker operations leads
Myeloid keynote and LILRB session
Trial-design session on Day 1 evening

Cell therapy CDMOs

CMC, manufacturing and programme leads
Scaling panel and Allogeneic Cellular Therapies
Day 1 drinks reception for follow-ups

CROs running IO trials

Clinical development and clinical operations
Combo keynote and adaptive trial design
1:1s with biotechs nearing first-in-human

Geography matters for a London sponsor. Delegates are 60% UK and Ireland and 40% rest of Europe, so one stand covers the Oxford, Cambridge and London biotech base and a continental pipeline that, on this year’s agenda, reaches from Faron in Helsinki to Merck KGaA in Darmstadt. It is an immuno-oncology meeting in London that also runs a biomarker and companion diagnostics stream next door, so the translational colleagues of the people you meet in Stream 1 are in the same building for both days.

Packages

Which package fits an IO sponsor in London

Platinum, Gold and Silver sponsors choose their stream, so every option below puts your talk and booth in front of the Stream 1 audience.

Best fit

Platinum, Stream 1

Day 1 Platinum slots in Stream 1 run at 11:15, 12:45, 14:15, 15:30 and 16:45, between the CARKey talk and the scaling panel. That is where CDMOs and tool vendors want to be heard.

30-minute Day 1 talk plus Q&A
10 pre-scheduled 1:1 meetings
8 team + 8 client passes, 10 x 6 ft booth
Attendee list a week before, 1-minute video promotion

Gold, Stream 1

Day 2 pre-lunch slots sit around the LILRB and Allogeneic Cellular Therapies sessions. A strong fit for reagent and cell-analytics vendors.

30-minute Day 2 talk plus Q&A
6 pre-scheduled 1:1 meetings
6 team + 6 client passes, 10 x 6 ft booth
Half-page brochure advertisement

Exclusive 1:1 Meetings

For CROs whose sale happens in a quiet 20 minutes, not on a stage.

3, 5, 7 or 10 meetings of 20 minutes
2–4 passes plus drinks reception passes
Wishlist and delegate list with contacts
Logo and description in brochure and webpage

Model the pipeline value of 10 meetings against 6 for your average deal size.

Open the ROI calculator

Next steps

Planning your London IO presence

Shortlisting an immunotherapy conference for the UK in 2027?

Three questions settle it for most IO vendors. Does the agenda name the modalities you serve? Are the delegates the people who sign partner contracts? Can you meet them in private, not only at a stand? London answers with a named Stream 1 agenda, a 70% senior room last year and pre-scheduled 20-minute meetings chosen from full delegate profiles 10 days before the event.

If you also sell on the US West Coast, the San Diego cancer immunotherapy conference runs a month earlier with a different Stream 1 programme. For a view of every edition side by side, see the immuno-oncology summit overview. Background reading on where cell and gene therapy programmes need partners: the advanced therapies biomarker outlook.

Full tier details are on the London sponsorship opportunities page.

Tell us which Stream 1 modality you sell into and we will send the prospectus with the slots that fit.

Request the prospectus

Sponsorship ROI calculator

What could London 2027 be worth to your team?

Pick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.

1. Choose a package

Sponsorship packages

Exclusive 1:1 meeting packages

2. Your numbers

Average first-year deal value

Year-one value of a new pharma or biotech customer

Extra conversations at the event

Booth visits, networking and questions after your talk

Become a real opportunity

Share of conversations worth a proposal

Opportunities you usually win

Your typical close rate

Your total event budget

Sponsorship plus travel and team costs

Estimated return

expected first-year revenue for every £1 of your event budget

Pre-scheduled 1:1 meetings

Qualified conversations

New opportunities

Cost per conversation

Pipeline created

Expected revenue won

Get pricing and the prospectus for this package Or talk to our team about a custom package

Estimates only, based on the numbers you enter. Meetings and inclusions from the London 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Which stream should an IO tools or services vendor choose in London?

Stream 1, Next-Gen Immuno-Oncology, if your buyers run therapy programmes: cell therapy, multispecifics, myeloid checkpoints, combinations. Platinum, Gold and Silver sponsors choose their stream. Choose Stream 2 instead if your product is mainly a biomarker assay or companion diagnostic.

How many meetings can an IO sponsor expect in London?

Pre-scheduled 1:1 meetings depend on the package: 15 for Headline, 10 for Platinum, 6 for Gold, and 3, 5, 7 or 10 with the Exclusive 1:1 Meetings packages. Silver and Exhibitor have no pre-scheduled meetings. At London 2026, sponsors held 15–25 meetings each and more than 200 meetings took place across the event.

Are cell therapy CDMOs and IO CROs a good fit for this audience?

Yes. The London Stream 1 agenda includes a panel on scaling immunotherapies from discovery to commercialisation, a session on allogeneic cellular therapies and one on adaptive, biomarker-driven trial design. 55–60% of delegates come from biotech and pharma, and 45–50% are senior leaders.

When would our talk run in Stream 1?

Platinum sponsors get a 30-minute talk on Day 1 (3 March 2027). Gold sponsors get a 30-minute talk on Day 2 before lunch, and Silver sponsors a 15-minute talk on Day 2 after lunch. The Headline sponsor gives a welcome speech and a 30-minute Day 1 keynote across both streams.

We sell in Europe and the US. How does London relate to San Diego?

They are separate editions with the same package structure. San Diego is the launch edition on 10–11 February 2027 with its own Stream 1 agenda. London on 3–4 March 2027 reaches a delegate base that is 60% UK and Ireland and 40% rest of Europe.

Sponsor the Cancer Immunotherapy Conference in London

Get the prospectus and package availability